Literature DB >> 7592749

Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance.

L Beigelman1, J A McSwiggen, K G Draper, C Gonzalez, K Jensen, A M Karpeisky, A S Modak, J Matulic-Adamic, A B DiRenzo, P Haeberli.   

Abstract

A systematic study of selectively modified, 36-mer hammerhead ribozymes has resulted in the identification of a generic, catalytically active and nuclease stable ribozyme motif containing 5 ribose residues, 29-30 2'-O-Me nucleotides, 1-2 other 2'-modified nucleotides at positions U4 and U7, and a 3'-3'-linked nucleotide "cap." Eight 2'-modified uridine residues were introduced at positions U4 and U7. From the resulting set of ribozymes, several have almost wild-type catalytic activity and significantly improved stability. Specifically, ribozymes containing 2'-NH2 substitutions at U4 and U7, or 2'-C-allyl substitutions at U4, retain most of their catalytic activity when compared to the all-RNA parent. Their serum half-lives were 5-8 h in a variety of biological fluids, including human serum, while the all-RNA parent ribozyme exhibits a stability half-life of only approximately 0.1 min. The addition of a 3'-3'-linked nucleotide "cap" (inverted T) did not affect catalysis but increased the serum half-lives of these two ribozymes to > 260 h at nanomolar concentrations. This represents an overall increase in stability/activity of 53,000-80,000-fold compared to the all-RNA parent ribozyme.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7592749     DOI: 10.1074/jbc.270.43.25702

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  Rapid kinetic characterization of hammerhead ribozymes by real-time monitoring of fluorescence resonance energy transfer (FRET).

Authors:  K K Singh; R Parwaresch; G Krupp
Journal:  RNA       Date:  1999-10       Impact factor: 4.942

2.  Adenovirus-mediated expression of a ribozyme to c-myb mRNA inhibits smooth muscle cell proliferation and neointima formation in vivo.

Authors:  D G Macejak; H Lin; S Webb; J Chase; K Jensen; T C Jarvis; J M Leiden; L Couture
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

3.  HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture.

Authors:  B Bramlage; E Luzi; F Eckstein
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

4.  Developing aptamers into therapeutics.

Authors:  R R White; B A Sullenger; C P Rusconi
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

Review 5.  Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics.

Authors:  N Usman; L M Blatt
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

Review 6.  Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function.

Authors:  L M Khachigian
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

7.  Small, efficient hammerhead ribozymes.

Authors:  M J McCall; P Hendry; A A Mir; J Conaty; G Brown; T J Lockett
Journal:  Mol Biotechnol       Date:  2000-01       Impact factor: 2.695

8.  Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells.

Authors:  Frank Czauderna; Melanie Fechtner; Sibylle Dames; Hüseyin Aygün; Anke Klippel; Gijsbertus J Pronk; Klaus Giese; Jörg Kaufmann
Journal:  Nucleic Acids Res       Date:  2003-06-01       Impact factor: 16.971

9.  RNA cleaving '10-23' DNAzymes with enhanced stability and activity.

Authors:  Steffen Schubert; Deniz C Gül; Hans-Peter Grunert; Heinz Zeichhardt; Volker A Erdmann; Jens Kurreck
Journal:  Nucleic Acids Res       Date:  2003-10-15       Impact factor: 16.971

Review 10.  Protein-binding oligonucleotides: the next frontier in antithrombotic therapy.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2004-04       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.